Dosage of Abacavir, Dolutegravir, and Lamivudine in AKI Patients
In patients with acute kidney injury (AKI), abacavir and dolutegravir require no dose adjustment, while lamivudine dosing depends on creatinine clearance (CrCl)—use 150 mg first dose then 50 mg daily for CrCl 30-49 mL/min, 35 mg first dose then 25 mg daily for CrCl 15-29 mL/min, and 35 mg first dose then 15 mg daily for CrCl 5-14 mL/min.
Abacavir Dosing in AKI
- No dose adjustment required regardless of renal function 1
- Standard dose: 300 mg twice daily or 600 mg once daily
- Abacavir is primarily metabolized hepatically, not renally eliminated
- Safe across all levels of kidney dysfunction including hemodialysis 1
Dolutegravir Dosing in AKI
For CrCl >30 mL/min:
- Use standard dose of 50 mg once daily 2
- No adjustment needed for integrase inhibitor-naive patients
For CrCl <30 mL/min:
- Use 50 mg once daily with close monitoring 2
- Dolutegravir concentrations may decrease by 40% in severe renal impairment
- Clinical significance remains uncertain, but this reduction is generally well-tolerated in treatment-naive patients
- Caution: Integrase-experienced patients with resistance mutations may be at increased risk for virologic breakthrough 2
Lamivudine Dosing in AKI
The FDA-approved dosing for lamivudine in renal impairment is 3, 4:
| Creatinine Clearance | First Dose | Maintenance Dose |
|---|---|---|
| ≥50 mL/min | 150 mg | 150 mg twice daily or 300 mg once daily |
| 30-49 mL/min | 150 mg | 100 mg once daily |
| 15-29 mL/min | 150 mg | 50 mg once daily |
| 5-14 mL/min | 50 mg | 25 mg once daily |
| <5 mL/min | 50 mg | 25 mg once daily |
However, emerging real-world evidence challenges these conservative recommendations:
Recent studies demonstrate that higher-than-recommended lamivudine doses are well-tolerated and effective in patients with renal impairment 5, 6, 7. One study showed 77% of patients received higher-than-recommended lamivudine doses with excellent viral suppression (99% <200 copies/mL) and no toxicity 5. Another study found that full-dose lamivudine (300 mg daily) was used safely in 32% of patients with eGFR <30 mL/min 5.
Practical approach based on current evidence:
- For CrCl 30-49 mL/min: Consider 150 mg daily (rather than 100 mg) to avoid liquid formulations and improve adherence 7
- For CrCl 15-29 mL/min: Consider 100-150 mg daily 5, 7
- For hemodialysis: Some centers successfully use 100-150 mg daily 5, 7
- Monitor lactic acid levels if using higher doses, though lamivudine has not been associated with increased lactic acidosis risk even at elevated concentrations 7
Critical Considerations for AKI
Key differences between AKI and CKD:
- AKI is a dynamic, rapidly changing condition unlike stable CKD 8, 9
- Renal function may improve or worsen unpredictably
- Monitor CrCl frequently (every 1-3 days initially) and adjust doses accordingly
- The abacavir/lamivudine/dolutegravir combination is particularly advantageous because only lamivudine requires adjustment
Monitoring strategy:
- Check CrCl at baseline and every 1-3 days during acute phase
- Monitor HIV viral load at weeks 4,12, and 24 after any dose adjustment
- Check lactic acid if using higher lamivudine doses (though risk is low)
- Assess for drug accumulation signs: nausea, fatigue, headache
Single-Tablet Regimen Considerations
The abacavir/lamivudine/dolutegravir fixed-dose combination (Triumeq) contains lamivudine 300 mg and is not recommended when CrCl <50 mL/min per FDA labeling 1. However, recent data suggest this single-tablet regimen may be safe and effective across the eGFR spectrum 5, 6.
For patients requiring dose adjustment:
- Use individual components to allow lamivudine dose modification
- Abacavir 600 mg once daily + dolutegravir 50 mg once daily + adjusted lamivudine dose
- This maintains adherence while allowing appropriate renal dosing
Common pitfall: Avoid using liquid formulations when possible, as they are associated with lower virologic suppression rates in adults 4. Higher-strength tablets with appropriate dose adjustment are preferred 5, 7.